• Joshua J Griffiths, Carlos A Zarate, and J J Rasimas.
• Department of Psychiatry, University of Colorado, Denver, Colorado.
• Am J Prev Med. 2014 Sep 1; 47 (3 Suppl 2): S195S203S195-203.

AbstractWe summarize outcomes for several pharmacologic and neurostimulatory approaches that have been considered potential treatments to reduce suicide risk, namely, by reducing suicide deaths, attempts, and ideation in various clinical populations. Available treatments include clozapine, lithium, antidepressants, antipsychotics, electroconvulsive therapy, and transcranial magnetic stimulation. The novel repurposing of ketamine as a potential suicide risk-mitigating agent in the acute setting is also discussed. Research pathways to better understand and treat suicidal ideation and behavior from a neurobiological perspective are proposed in light of this foundation of information and the limitations and challenges inherent in suicide research. Such pathways include trials of fast-acting medications, registry approaches to identify appropriate patients for trials, identification of biomarkers, neuropsychological vulnerabilities, and endophenotypes through the study of known suicide risk-mitigating agents in hope of determining mechanisms of pathophysiology and the action of protective biological interventions.Copyright © 2014 American Journal of Preventive Medicine. All rights reserved.

18 keywords...

hide…